Search

Your search keyword '"Crohn's disease -- Drug therapy"' showing total 17 results
Start Over Descriptor "Crohn's disease -- Drug therapy" Journal scrip world pharmaceutical news
17 results on '"Crohn's disease -- Drug therapy"'

1. Crohn's disease disappointment for Celltech. (test results for disease treatment Humicade)

Subjects
Celltech Ltd. -- Research, Biological products industry -- Research, Anti-antibodies -- Research, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Humicade (Medication) -- Research
Abstract

Information on Celltech's Phase III of research of its anti-TNF antibody CDP 571 (Humicade) as treatment for Crohn's disease is offered. Additional information on the drug's therapeutic efficiency is included.

Published
2002

2. Remicade's long-term benefit in Crohn's

Subjects
Centocor Inc. -- Product development, Biological products industry -- Product development, Crohn's disease -- Drug therapy, Fistula, Intestinal -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Remicade (Medication) -- Product development
Abstract

Two clinical studies on Centocor's Remicade for treatment of Crohn's disease are discussed. Both Crohn's patients with fistulae and non-fistulising patients were used in the studies, which Centocor hopes will lead to broader labeling for the product.

Published
2002

3. NICE OKs Remicade for Chron's

Subjects
United Kingdom. National Institute for Clinical Excellence -- Laws, regulations and rules, Schering-Plough Corp. -- Product information, Centocor Inc. -- Product information, Pharmaceutical industry -- Laws, regulations and rules, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Remicade (Medication) -- Laws, regulations and rules
Abstract

The United Kingdom's National Institute for Clinical Excellence recommended that Schering-Plough's and Centocor's drug Remicade be used for patients with extreme Crohn's disease.

Published
2002

4. Celltech and Biogen sign CDP571 deal. (development of Crohn's disease treatment Humicade)

Subjects
Celltech Ltd. -- Contracts, Biogen Inc. -- Contracts, Biological products industry -- Contracts, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Humicade (Medication) -- Contracts
Abstract

Information on Celltech's contract with Biogen to develop and market Crohn's disease treatment Humicade is offered. Additional information on Humicade agreement is included.

Published
2002

5. Remicade CHF contra-indication in EC

Subjects
Schering-Plough Ltd. -- Labeling, Centocor Inc. -- Product information, Crohn's disease -- Drug therapy, Rheumatoid arthritis -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Remicade (Medication) -- Labeling
Abstract

The European Commission ordered revised labeling for Schering-Plough and Centocor's Remicade, which could cause problems for patients with heart disease. The drug is used to treat patients with Crohn's disease and rheumatoid arthritis. Phase II study results are discussed.

Published
2002

6. New approaches to tackle Crohn's disease

Subjects
Elan Pharmaceuticals Inc. -- Research, Biogen Inc. -- Research, Isis Pharmaceuticals Inc. -- Research, Pharmaceutical industry -- Research, Biological products industry -- Research, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Tysabri (Medication) -- Research
Abstract

Information on studies on Elan/Biogen's Antegren and ISIS Pharmaceuticals' ISIS 2302 - Crohn's disease treatments is offered. Additional information on the efficiency of both drugs in treating Crohn's disease is also included.

Published
2001

7. Centocor's infliximab launched in US

Subjects
Centocor Inc. -- Product introduction -- 00301465, Pharmaceutical industry -- Product introduction, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Remicade (Medication) -- Product introduction
Published
1998

8. Remicade approval boosts Celltech

Subjects
Centocor Inc. -- Licensing agreements -- 00301465, Celltech Group PLC -- Licensing agreements -- 00144294, Pharmaceutical industry -- Licensing agreements, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Remicade (Medication) -- Licensing agreements
Published
1998

9. Mixed news for Centocor on Avakine

Subjects
Centocor Inc. -- Product information, Biological products industry -- Product information, Monoclonal antibodies -- Research, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Avakine (Medication) -- Research
Published
1998

11. Isis' positive Crohn's disease trial

Subjects
Isis Pharmaceuticals Inc. -- Research -- 00210297, Biological products industry -- Research, Nucleotides -- Research, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries
Published
1997

12. Clinical trials round-up

Subjects
Centocor Inc. -- Product development -- 00301465, Wyeth-Lederle -- Product development, Cortecs Ltd. -- Product development, GenVec Inc. -- Product development -- 00292796, Cell Genesys Inc. -- Product development -- 00252541, Merck & Company Inc. -- Product development -- 00305661, Ibex Technologies Inc. (El Dorado Hills, California) -- Product development -- 00234894, Emisphere Technologies Inc. -- Product development -- 00200169, Biological products industry -- Product development, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries
Published
1996

13. Astra launches Crohn's drug in UK

Subjects
Astra AB -- Product information, Pharmaceutical industry -- Product information, Steroids (Drugs) -- Health aspects, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Entocort CR (Medication) -- Health aspects
Published
1996

14. Celltech's Ab beneficial in Crohn's

Subjects
Celltech Ltd. -- Research, Bayer AG -- Research -- 00136009, Pharmaceutical industry -- Research, Antibodies -- Research, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries
Published
1995

15. Astra's salbutamol Turbuhaler launch

Subjects
Astra AB -- Product introduction, Pharmaceutical industry -- Product introduction, Drug delivery devices -- Product introduction, Gastrointestinal agents -- Health aspects, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Entocort (Medication) -- Health aspects
Published
1995

16. Procyte completes Iamin-IB trials in bowel disease

Subjects
ProCyte Corp. -- Product development, Pharmaceutical industry -- Product development, Crohn's disease -- Drug therapy, Ulcerative colitis -- Drug therapy, Business, Pharmaceuticals and cosmetics industries
Published
1994

17. Novel approaches to inflammatory bowel disease

Subjects
Sandoz Pharmaceuticals Corp. -- Product information, Kabi Inc. -- Product information, Centocor Inc. -- Product information, Astra Pharmaceutical Products Inc. -- Product information, Inflammatory bowel diseases -- Drug therapy, Transdermal medication -- Dosage and administration, Ulcerative colitis -- Drug therapy, Monoclonal antibodies -- Usage, Corticosteroids -- Dosage and administration, Crohn's disease -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Sandimmune (Medication) -- Dosage and administration, Nicorette (Chewing gum) -- Usage
Published
1993

Catalog

Books, media, physical & digital resources
See catalog results